Epizyme Inc. (EPZM) Rating Reiterated by Leerink Swann
Epizyme Inc. (NASDAQ:EPZM)‘s stock had its “outperform” rating reissued by stock analysts at Leerink Swann in a research note issued to investors on Friday.
A number of other analysts have also recently weighed in on the company. Zacks Investment Research raised Epizyme from a “sell” rating to a “hold” rating in a research report on Wednesday, August 10th. HC Wainwright reissued a “buy” rating on shares of Epizyme in a research report on Tuesday, August 9th. JMP Securities reissued a “buy” rating and issued a $28.00 price objective on shares of Epizyme in a research report on Thursday, June 23rd. Cowen and Company reissued a “buy” rating on shares of Epizyme in a research report on Monday, June 20th. Finally, Mizuho reissued a “buy” rating and issued a $18.00 price objective on shares of Epizyme in a research report on Monday, June 20th. One analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. Epizyme presently has an average rating of “Buy” and an average target price of $23.11.
Shares of Epizyme (NASDAQ:EPZM) traded down 1.79% during mid-day trading on Friday, reaching $9.35. The company’s stock had a trading volume of 122,767 shares. The firm’s market cap is $541.89 million. Epizyme has a 12-month low of $7.02 and a 12-month high of $18.29. The firm’s 50-day moving average price is $8.70 and its 200 day moving average price is $10.14.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/12/epizyme-inc-epzm-rating-reiterated-by-leerink-swann.html
Epizyme (NASDAQ:EPZM) last posted its quarterly earnings data on Monday, August 8th. The biopharmaceutical company reported ($0.49) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.52) by $0.03. Epizyme had a negative return on equity of 43.05% and a negative net margin of 5,174.49%. On average, analysts expect that Epizyme will post ($2.20) EPS for the current year.
In other news, insider Robert A. Copeland sold 4,000 shares of the business’s stock in a transaction dated Monday, August 1st. The stock was sold at an average price of $10.37, for a total value of $41,480.00. Following the completion of the transaction, the insider now owns 35,538 shares of the company’s stock, valued at approximately $368,529.06. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 25.40% of the stock is owned by insiders.
Institutional investors have recently modified their holdings of the stock. Primecap Management Co. CA raised its position in shares of Epizyme by 24.3% in the first quarter. Primecap Management Co. CA now owns 6,518,627 shares of the biopharmaceutical company’s stock valued at $79,006,000 after buying an additional 1,273,000 shares in the last quarter. Franklin Resources Inc. acquired a new position in shares of Epizyme during the first quarter valued at $14,544,000. CQS Cayman LP acquired a new position in shares of Epizyme during the second quarter valued at $6,502,000. Deerfield Management Co. acquired a new position in shares of Epizyme during the second quarter valued at $6,372,000. Finally, BlackRock Fund Advisors raised its position in shares of Epizyme by 42.0% in the first quarter. BlackRock Fund Advisors now owns 1,698,516 shares of the biopharmaceutical company’s stock valued at $20,586,000 after buying an additional 502,627 shares in the last quarter. 80.79% of the stock is owned by institutional investors and hedge funds.
Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs.
Receive News & Ratings for Epizyme Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Epizyme Inc. and related companies with MarketBeat.com's FREE daily email newsletter.